DNAprint Genomics (DNAG)

[mingwan0]

Synergy in practice

http://www.primepharmaceutical.com/overview.htm

Prime has ensured a long-term source of scientific technology through a strategic alliance with Utek Corporation, a Florida based, technology transfer company. Utek (UTK) is a public company listed on the American Stock Exchange, which has entered into an agreement whereby they will source and introduce appropriate technology acquisition opportunities for Prime. Utek, with its advisory board of 18 scientists, of which 3 are Nobel prizewinners, has recognized the huge potential of Prime Pharmaceutical Corporation and made a substantial equity investment in the company.

http://philadelphia.bizjournals.com/tampabay/stories/2003/05/19/focus2.html

"Our preference is to help local companies," said Dr. Douglas Weiland, managing director and principal at Athena Capital Partners Inc. in Tampa.

Athena also works to relocate life sciences businesses to the Bay area. The firm focuses on investments between $1 million and $20 million, about 70 percent to 80 percent of which are in the life sciences industry.

Weiland, a former orthopedic surgeon, works with local companies such as DNAPrint genomics Inc. in Sarasota and Apollo Pharmaceuticals LLC in Tampa. He also is working on bringing CBD Technologies Inc., an Israeli company, to the Bay area.

http://www.primepharmaceutical.com/26Aug2003.htm

August 26, 2003
Press Release
Prime Pharmaceutical Corporation

TORONTO – Prime Pharmaceutical Corporation (Prime) is pleased to announce the receipt of all upfront fees and confirm the final closing of a Licensing Agreement with Apollo Pharmaceutical LLC (Apollo), pursuant to the Private Placement/Licensing Agreement with Athena Capital Partners Inc. (Athena), dated May 6th, 2003 as set forth in a prior news release.

License Agreement

Prime has agreed to license to a US joint venture company organized by Athena Capitals Partners Inc., Apollo Pharmaceuticals LLC., for an upfront fee and ongoing royalties, the exclusive rights to market and sell all of the current and future dermatology products of Prime worldwide except for Canada. These license agreements for various territories require performance standards as well as ongoing royalties. Prime has agreed to manage Apollo Pharmaceuticals, subject to the terms and conditions of a Management Contract. Upon the successful closing of a minimum placement $835,000 USD, Prime shall obtain a 20% equity ownership of Apollo Pharmaceuticals, in exchange for 970,000 Series A 5% preferred shares as per the offering. Prime will be guaranteed that no dilution will occur for a period of 24 months from the date the shares of Apollo Pharmaceuticals are issued to Prime. Prime shall also have the right of first refusal to the Canadian license to any products that Apollo Pharmaceuticals may develop or acquire outside the scope of the license agreements noted above.

http://www.sunbiz.org/scripts/corevt.exe?a1=DETNAM&n1=L03000016462&n2=FLAL

WCW ENTERPRISES, LLC

NAME CHANGE AMENDMENT 10/20/2003 OLD NAME WAS : APOLLO PHARMACEUTICALS, LLC

Registered Agent: WEISS, LISA R

http://www.athena-capital.com/

Athena Capital Partners, Inc. was formed in December of 2000 and received NASD approval in April of 2002. Our goal is to provide capital markets expertise for both emerging companies and alternative investment funds, including venture capital and hedge funds.

Principals

Lisa R. Weiss, CFA - Managing Director and Founder
Ms. Weiss has over 25 years of institutional investment experience as both a portfolio manager and sell-side analyst.

(Apart from DNAPrint Genomics, Athena "Clients" include Apollo Pharmaceuticals and Prime Pharmaceutical Corporation.)

http://biz.yahoo.com/bw/031120/205377_1.html

UTEK Corporation Appoints Hector Gomez, M.D., Ph.D., to Scientific Advisory Council
Thursday November 20, 10:29 am ET

PLANT CITY, Fla.--(BUSINESS WIRE)--Nov. 20, 2003--UTEK Corporation (AMEX:UTK - News) announced today that Hector J. Gomez, M.D., Ph.D., has joined UTEK's Scientific Advisory Council. Previously, Dr. Gomez served as a Senior Director of clinical research at Merck/MSDRL, Executive Director of Clinical Research at CIBA-GEIGY Corporation, VP of Medical Affairs at Vertex Pharmaceuticals and President and CEO of Transcend Therapeutics. Dr. Gomez is currently a Member of the Board of Directors of PRB Pharmaceuticals and Apollo Pharmaceuticals and is the Chairman of the Board of Directors of DNAprint Genomics.